Maxim Sees Compelling Value In AEterna Zentaris Inc. (AEZS)
Maxim Group analyst Jason Kolbert came out with a research report on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), after visiting with management in South Carolina and reviewing the company fundamentals. The analyst rates Aeterna Zentaris shares a Buy with a price target of $2.00, which represents a potential upside of 608% from where the stock is currently trading.
Kolbert wrote, “We left impressed that there is real and compelling value ahead in this company across multiple programs. We spent a good portion of our day focused on Macrilen. We conclude that Macrilen works, is a viable paradigm shift in the Adult Growth Hormone Deficiency (AGHD) marketplace and with even modest success, justifies the company’s current valuation. With the current test, insulin tolerance is long and burdensome vs. Macrilen, so we believe Macrilen could expand the market.”
Bottom line: “We see the current Macrilen trial as low risk, high reward. Other near-term catalysts should support and drive valuation.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 2.7% and a 42.0% success rate. Kolbert has a -59.5% average return when recommending AEZS, and is ranked #1223 out of 3624 analysts.
Out of the 4 analysts polled by TipRanks, 3 rate Aeterna Zentaris stock a Buy, while 1 rates the stock a Hold. With a return potential of 320.4%, the stock’s consensus target price stands at $1.19.